Neurotrophic factors are essential proteins that support neuronal survival, differentiation, synaptic plasticity, and function. Decline in neurotrophic signaling is a common feature of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. This page examines the major neurotrophic systems, their dysfunction in neurodegenerative diseases, and therapeutic strategies to restore neurotrophic support 1.
BDNF is the most widely studied neurotrophin in the brain:
- Receptors: TrkB (high affinity), p75NTR (low affinity)
- Signaling: TrkB autophosphorylation activates PI3K/Akt, MAPK/ERK, and PLCγ pathways
- Functions: Neuronal survival, synaptic plasticity, memory formation
- Expression: High in hippocampus and cortex
NGF was the first discovered neurotrophic factor:
- Receptors: TrkA (high affinity), p75NTR
- Signaling: TrkA activates similar pathways to TrkB
- Functions: Cholinergic neuron survival, peripheral innervation
- Expression: Basal forebrain cholinergic neurons
GDNF family ligands support dopaminergic and motor neurons:
- Receptors: GFRα1-4 (GPI-anchored), Ret (coreceptor)
- Signaling: GFRα/Ret complex activates PI3K/Akt and MAPK pathways
- Functions: Dopaminergic neuron survival, motor neuron support
- Expression: Midbrain, spinal cord
- Neurotrophin-3 (NT-3): Supports diverse neuronal populations
- Neurotrophin-4 (NT-4): Synaptic plasticity
- Ciliary Neurotrophic Factor (CNTF): Astrocyte-derived, neuroprotection
- Insulin-like Growth Factor (IGF-1): Metabolic and trophic support
- VEGF: Angiogenesis and neuroprotection
VEGF is a critical neurotrophic factor with dual roles in vascular and neural function:
- Angiogenesis: Promotes blood vessel formation
- Neuroprotection: Direct survival effects on neurons
- Neurogenesis: Supports stem cell niches
- Blood-brain barrier maintenance: Protects BBB integrity
- Reduced VEGF in AD brain
- Amyloid-beta impairs VEGF signaling
- Therapeutic potential of VEGF delivery
- VEGF protects dopaminergic neurons
- Reduced in PD substantia nigra
- Gene therapy approaches in development
- Motor neuron protection
- VEGF deficiency increases ALS risk
- VEGF gene therapy in trials
IGF-1 plays crucial roles in brain aging and neurodegeneration:
- Metabolic support: Glucose utilization in brain
- Trophic effects: Neuronal survival and growth
- Synaptic plasticity: Learning and memory
- Myelin maintenance: Oligodendrocyte support
- Reduced IGF-1 signaling in AD
- Peripheral IGF-1 affects CNS function
- Therapeutic potential being explored
- Dopaminergic neuron protection
- Neuroinflammation modulation
- Clinical trials ongoing
flowchart TD
A["Neurotrophic Factor"] --> B["Trk Receptor Dimerization"]
A --> C["p75NTR Receptor"]
B --> D["Trk Autophosphorylation"]
D --> E["PI3K/Akt Pathway"]
D --> F["MAPK/ERK Pathway"]
D --> GPLCγ P["athway"]
E --> H["Cell Survival"]
E --> I["Protein Synthesis"]
F --> J["Gene Expression"]
F --> K["Neurite Outgrowth"]
G --> L["Calcium Signaling"]
L --> H
C --> MNF-κB A["ctivation"]
C --> N["Apoptosis"](/entities/apoptosis)
M --> H
N --> O["Cell Death"]
BDNF dysfunction is a key feature in AD:
BDNF levels are reduced in AD brain, particularly in hippocampus. Serum BDNF correlates with cognitive decline. Key observations include:
- Decreased BDNF mRNA and protein in AD hippocampus and cortex
- Reduced BDNF in cerebrospinal fluid of AD patients
- Serum BDNF levels correlate with MMSE scores
- Amyloid-beta downregulates BDNF expression
Impaired TrkB signaling contributes to synaptic loss. Aβ disrupts TrkB signaling.
- Aβ oligomers reduce TrkB receptor expression
- Impaired downstream PI3K/Akt and MAPK/ERK signaling
- Reduced synaptic plasticity and memory formation
- TrkB cleavage and shedding increased in AD
Increased p75NTR expression promotes apoptosis in AD.
- p75NTR acts as death receptor when unoccupied by mature neurotrophins
- Pro-NGF/p75NTR signaling induces apoptosis in cholinergic neurons
- Increased p75NTR in AD brain correlates with neurodegeneration
- Balance between Trk and p75NTR signaling determines cell fate
NGF support is impaired in basal forebrain cholinergic neurons.
- NGF synthesized in hippocampus and cortex
- Retrograde transport to basal forebrain required for neuron survival
- Impaired transport in AD due to tau pathology
- Loss of cholinergic neurons correlates with cognitive decline
BDNF delivery shows promise in preclinical models.
- AAV-BDNF gene therapy in animal models
- Small molecule TrkB agonists
- Exercise and environmental enrichment
Key neurotrophins in AD:
- BDNF: Reduced hippocampal expression
- NGF: Impaired retrograde transport
- NT-3: Altered expression
GDNF and BDNF support is critical for dopaminergic neurons:
GDNF: Highly protective of dopaminergic neurons. Clinical trials showed mixed results.
- GDNF rescues dopaminergic neurons in vitro and in vivo
- Intraputaminal GDNF infusion in clinical trials
- AAV-GDNF gene therapy approaches
- challenges include delivery and distribution
BDNF: Supports dopaminergic neuron survival. Reduced in PD substantia nigra.
- BDNF expressed in striatum and substantia nigra
- Supports dopaminergic neuron maintenance
- Reduced in PD SNc
- TrkB signaling impaired in PD
GFRα signaling: GDNF family receptor dysfunction in PD.
- GFRα1-4 receptors mediate GDNF family signaling
- Ret receptor tyrosine kinase required for signaling
- Mutations in GFRα pathways linked to PD risk
- GBA influences GDNF pathway function
Retrograde transport: Impaired transport of trophic factors.
- Axonal transport defects in PD
- Tau and α-syn pathology affects transport
- Kinesin/dynein dysfunction
Key genes in PD neurotrophin signaling:
- GDNF - Glial cell line-derived neurotrophic factor
- RET - GDNF receptor
- GFRΑ1 - GDNF family receptor alpha 1
- GFRΑ2 - GDNF family receptor alpha 2
- NRTN - Neurturin
- ARTN - Artemin
Neurotrophic support is critical for motor neurons:
CNTF: CNTF levels reduced in ALS. CNTF knockout mice develop motor neuron disease.
- Reduced CNTF in ALS spinal cord
- CNTF delivery shows protective effects
- AAV-CNTF gene therapy approaches
GDNF: Protective of motor neurons. Delivered via gene therapy in trials.
- GDNF protects motor neurons
- AAV-GDNF in clinical trials
- Challenges with delivery to spinal cord
BDNF: Supports motor neurons. Clinical trials showed limited efficacy.
- BDNF trial in ALS showed mixed results
- Delivery challenges limit efficacy
- Cell-based BDNF delivery approaches
VEGF: Motor neuron protection. VEGF deficiency increases ALS risk.
- VEGF regulates motor neuron survival
- VEGF deficiency in ALS models
- VEGF gene therapy approaches
Key genes in ALS neurotrophin signaling:
- CNTF - Ciliary neurotrophic factor
- VEGFA - Vascular endothelial growth factor A
- GDNF - Glial cell line-derived neurotrophic factor
- VEGFR1/2 - VEGF receptors
- FLT1 - VEGF receptor 1
- cAMP response element-binding protein (CREB): Reduced CREB activity
- Activity-dependent expression: Reduced neuronal activity
- Epigenetic changes: DNA methylation affects neurotrophin genes
- Transcription factor dysfunction: Reduced Npas1, Npas4
See Epigenetic Alterations in Neurodegeneration for detailed information.
- Axonal transport defects: Neurotrophin cargo fails to reach cell bodies
- Cytoskeletal disruption: Tau pathology affects transport
- Molecular motor dysfunction: Kinesin/dynein impairment
- TrkB cleavage: Aβ promotes TrkB shedding
- Receptor trafficking: Impaired sorting to membranes
- Downstream signaling: PI3K/Akt pathway impairment
- Neuroinflammation: Glia become less supportive
- Oxidative stress: Damages neurotrophin expression systems
- Metabolic dysfunction: Reduces neurotrophin production
BDNF delivery:
- Recombinant protein delivery
- AAV gene therapy
- Cell-based delivery
GDNF delivery:
- Intraputaminal infusion (clinical trials)
- AAV gene therapy
- Protein delivery
NGF delivery:
- Cholinergic neuron support
- AAV gene therapy approaches
TrkB agonists:
- 7,8-DHF (7,8-dihydroxyflavone)
- BDNF mimetics
- Amitriptyline (TrkB activator)
GDNF family agonists:
- Small molecule GFRα1 agonists
- Ret agonists
PI3K/Akt activators:
- Akt activators
- mTOR modulators
CREB activators:
- Phosphodiesterase inhibitors
- CREB-binding protein (CBP) modulators
- AAV-BDNF: In clinical trials
- AAV-GDNF: In clinical trials
- AAV-NT-3: Preclinical
- Cell-based delivery: Stem cells engineered to secrete neurotrophins
¶ Lifestyle and Environmental Factors
- Exercise: Increases BDNF expression
- Cognitive stimulation: Activity-dependent BDNF
- Diet: Caloric restriction, omega-3 fatty acids
- Sleep: Sleep deprivation reduces BDNF
- BDNF - Brain-derived neurotrophic factor
- NGF - Nerve growth factor
- GDNF - Glial cell line-derived neurotrophic factor
- NTF3 - Neurotrophin-3
- NTF4 - Neurotrophin-4
- CNTF - Ciliary neurotrophic factor
- VEGFA - Vascular endothelial growth factor A
- NTRK2 - TrkB receptor
- NTRK1 - TrkA receptor
- RET - GDNF receptor
- GFRA1 - GFRα1 receptor
- CREB1 - CREB transcription factor